ABSTRACT
OBJECTIVES: To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. METHODS: We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. RESULTS: A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A 'core set' of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. CONCLUSIONS: A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.
Subject(s)
Lupus Erythematosus, Systemic/diagnosis , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Delphi Technique , Evidence-Based Medicine/methods , Humans , Long-Term Care/methods , Long-Term Care/standards , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/therapy , Lupus Nephritis/diagnosis , Opportunistic Infections/complications , Opportunistic Infections/diagnosis , Risk FactorsABSTRACT
Infections can act as environmental triggers that induce or promote systemic lupus erythematosus (SLE) in genetically predisposed individuals. New technologies, developed recently, enable simultaneous assessment of multiple antibodies. Antibodies to specific infectious agents may shed light into the mechanisms of induction of SLE. The aim of this study was to investigate the prevalence of seropositivity and the titers of antibodies to bacterial, viral, and parasitic agents in SLE patients compared with non-autoimmune controls. Sera from 260 individuals (120 SLE patients and 140 controls) were tested by the BioPlex 2200 Multiplexed Immunoassay method (BioRad) for the prevalence and titers of antibodies to eight infectious agents (Epstein-Barr virus: early antigen IgG, nuclear antigen IgG, viral capsid antigen IgG and IgM, heterophile IgM; cytomegalovirus IgG and IgM; Toxoplasma gondii IgG and IgM; rubella IgG and IgM; Treponema pallidum TPr15G, TPr17G, TPr47G; herpes simplex virus type 1 and 2 IgG; hepatitis C virus and hepatitis B core antibodies. Cytomegalovirus IgM and Epstein-Barr virus early antigen IgG (but not other Epstein-Barr virus antigens) were significantly more prevalent in SLE patients than in controls. Conversely, positive titers of hepatitis B core and rubella IgG antibodies were less prevalent in the SLE patients than in controls. Other differences in titer positivity prevalence were not detected between patients and controls. The titers of the cytomegalovirus IgM, Toxoplasma IgG, Epstein-Barr virus early antigen, and viral capsid antigen IgG antibodies were significantly higher in SLE compared with controls. Our data suggest the importance of previous exposure to infectious agents in the induction and the prevention of SLE.
Subject(s)
Antibodies, Protozoan , Antibodies, Viral , Lupus Erythematosus, Systemic , Adult , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Cytomegalovirus/immunology , Female , Hepacivirus/immunology , Herpesvirus 4, Human/immunology , Humans , Infections/blood , Infections/immunology , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Simplexvirus/immunology , Toxoplasma/immunology , Treponema pallidum/immunologyABSTRACT
Antiphospholipid syndrome is characterized by thrombosis and pregnancy loss. Infections are generally associated with autoimmune diseases, but in the setting of antiphospholipid syndrome this link has been suggested as having a pathogenic role. In this study, 98 patients with antiphospholipid syndrome were screened for antibodies directed to several infectious agents. The main finding in this study is the significantly higher prevalence of IgM antibodies to toxoplasma and rubella. This novel finding suggests that these infections might be associated with antiphospholipid syndrome. As autoimmune diseases and, in particular, antiphospholipid syndrome are associated with infections, mainly the catastrophic type of the syndrome, this finding implies that a current infection with these agents, i.e. toxoplasma and rubella, might either be related to the pathogenesis of antiphospholipid syndrome or alternatively to its manifestations.
Subject(s)
Antiphospholipid Syndrome , Infections , Thrombosis/physiopathology , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/physiopathology , Female , Humans , Immunoglobulin M/blood , Immunoglobulin M/immunology , Infections/complications , Infections/epidemiology , Pregnancy , Rubella/immunology , Toxoplasma/immunologyABSTRACT
Different types of infection are implicated in the pathogenesis of autoimmune thyroid diseases (AITD) through molecular mimicry or other mechanisms, but their role is disputed. Human studies support direct or indirect evidence of involvement of some viral and bacterial agents, but reports have provided conflicting and inconclusive results. Using a new automated multiplex array platform for the detection of antibodies, we determined seroreactivity against Toxoplasma gondii, Treponema pallidum, rubella virus, cytomegalovirus, and Epstein-Barr virus in a large group of Italian AITD patients and healthy controls. Only IgG concentrations against T. gondii were significantly higher in AITD patients than in controls, suggesting that these protozoa may be involved in the initiation of both Hashimoto's thyroiditis and Graves' disease.
Subject(s)
Antibodies/analysis , Infections/immunology , Protein Array Analysis , Thyroiditis, Autoimmune/immunology , Animals , Cytomegalovirus/immunology , Herpesvirus 4, Human/immunology , Humans , Infections/microbiology , Infections/parasitology , Infections/virology , Proteomics , Rubella virus/immunology , Thyroiditis, Autoimmune/microbiology , Thyroiditis, Autoimmune/parasitology , Thyroiditis, Autoimmune/virology , Toxoplasma/immunology , Treponema pallidum/immunologyABSTRACT
Autoimmune rheumatic diseases are generally considered as a multifactorial aetiology, mainly genetic susceptibility combined with environmental triggers of which bacteria are considered one of the most prominent. Among the rheumatic diseases where bacterial agents are more clearly involved as triggers are: reactive arthritis (ReA), rheumatic fever (RF) and Lyme disease. The role of bacterial infections in inducing other seronegative spondyloarthritis and antiphospholipid antibody syndrome has been hypothesized but is still not proven. The classic form of ReA is associated with the presence of HLA-B27 and is triggered by the urethritis or enteritis causing pathogens Chlamydia trachomatis and the enterobacteria Salmonella, Shigella, and Yersinia, respectively. But several other pathogens such as Brucella, Leptospira, Mycobacteria, Neisseria, Staphylococcus and Streptococcus have also been reported to cause ReA. RF is due to an autoimmune reaction triggered by an untreated throat infection by Streptococcus pyogenes in susceptible individuals. Carditis is the most serious manifestation of RF and HLA-DR7 is predominantly observed in the development of valvular lesions. Lyme disease is a tick-transmitted disease caused by the spirochete Borrelia burgdorferi. Knowledge is limited about how this spirochete interacts with human tissues and cells. Some data report that Borrelia burgdorferi can manipulate resident cells towards a pro- but also anti-inflammatory reaction and persist over a long period of time inside the human body or even inside human cells.
Subject(s)
Autoimmune Diseases/microbiology , Bacterial Infections/complications , Bacterial Infections/immunology , Rheumatic Diseases/immunology , Rheumatic Diseases/microbiology , Autoimmune Diseases/immunology , Humans , ProhibitinsSubject(s)
Arthritis, Rheumatoid/immunology , Autoantibodies/immunology , Carotid Artery Diseases/immunology , Peptides, Cyclic/immunology , Aged , Arthritis, Rheumatoid/diagnostic imaging , Carotid Artery Diseases/diagnostic imaging , Case-Control Studies , Female , Humans , Male , Middle Aged , UltrasonographyABSTRACT
To date, it is believed that the origin of autoimmune diseases is one of a multifactorial background. A genetic predisposition, an immune system malfunction or even backfire, hormonal regulation, and environmental factors all play important roles in the pathogenesis of autoimmune diseases. Among these environmental factors, the role of infection is known to be a major one. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are considered to be notorious as they are consistently associated with multiple autoimmune diseases. A cohort of 1595 serum samples, of 23 different autoimmune disease groups, was screened for evidence of prior infection with EBV and CMV. All samples were screened for antibodies against EBV nuclear antigen-1 (IgG), EBV viral capsid antigen (IgG and IgM), EBV early antigen (IgG), EBV heterophile antibody, and CMV (IgG and IgM) antibodies using Bio-Rad's BioPlex 2200. A new association is proposed between EBV and polymyositis, as results show a significant increase in titers of various EBV target analytes when compared with healthy controls. Our results also support prior information suggesting the association between EBV and multiple autoimmune diseases, including SLE, antiphospholipid syndrome, rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, giant cell arthritis, Wegener's granulomatosis, and polyarteritis nodosa (PAN). Elevated CMV IgG titers were observed in sera of SLE patients. Our data support the theory that EBV is notoriously associated with many autoimmune diseases. CMV appears to be associated to autoimmune diseases as well, yet establishing this theory requires further investigation.
Subject(s)
Antibodies, Viral/blood , Autoimmune Diseases/virology , Cytomegalovirus Infections/virology , Epstein-Barr Virus Infections/virology , Antigens, Viral/immunology , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Cytomegalovirus/immunology , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/immunology , Epstein-Barr Virus Infections/epidemiology , Epstein-Barr Virus Infections/immunology , Herpesvirus 4, Human/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin M/bloodABSTRACT
Antiphospholipid and anti-oxidized LDL (anti-oxLDL) antibodies are associated with thrombosis and atherosclerosis. Rheumatoid arthritis (RA) is characterized by excess atherosclerosis and cardiovascular diseases. Our aim was to determine whether antiphospholipid and anti-oxLDL antibodies are associated with early atherosclerotic changes in RA. The levels of IgG and IgM anticardiolipin, IgG and IgM anti-beta-2-glycoprotein-I and anti-oxLDL autoantibodies have been evaluated in 82 patients having RA. Carotid artery intima-media thickness (IMT) was measured in the carotid arteries in the common carotid, bifurcation and internal carotid arteries. Elevated levels of IgG anticardiolipin antibodies were detected in 17 of 82 (21%) RA patients, including 7 with medium-to-high levels considered being clinically relevant. These patients had significantly elevated mean carotid and carotid bifurcation IMT compared with RA patients without elevated anticardiolipin. No such association was found regarding other autoantibodies tested. Anticardiolipin antibodies are prevalent in RA and are associated with early atherosclerotic changes, supporting a rational for measuring them in RA, and upon detection treat the patients in order to decrease chances of atherosclerosis progression and thrombosis.
Subject(s)
Antibodies, Anticardiolipin/blood , Arthritis, Rheumatoid/complications , Carotid Arteries/pathology , Carotid Artery Diseases/pathology , Lipoproteins, LDL/immunology , Tunica Intima/pathology , Aged , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/pathology , Atherosclerosis/blood , Atherosclerosis/complications , Atherosclerosis/immunology , Carotid Artery Diseases/immunology , Female , Humans , Male , Middle AgedABSTRACT
OBJECTIVE: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anticyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA). METHODS: We assembled a training set, consisting of 60 patients with RA, all fulfilling the revised criteria of the American College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP was measured by latex turbidimetric immunoassay. RESULTS: The levels of anti-CCP antibody titers and ESR were significantly higher in patients with erosive disease than those in non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC) of anti-CCP was significantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not find significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as ESR or CRP. However, we confirmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of correlation was more significant in non-erosive patients. CONCLUSION: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP and ESR in patients with erosive RA.
Subject(s)
Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/immunology , Autoantibodies/blood , Peptides, Cyclic/immunology , Aged , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/enzymology , Biomarkers/blood , Blood Sedimentation , C-Reactive Protein/metabolism , Female , Humans , Male , Matrix Metalloproteinase 3/blood , Middle Aged , Predictive Value of Tests , Rheumatoid Factor/blood , Sensitivity and SpecificityABSTRACT
BACKGROUND: Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both. OBJECTIVE: To present patients who exhibited various inflammatory diseases accompanied with vasculitic peripheral neuropathies for which intravenous immunoglobulin (IVIg) was used for treatment. METHODS: Six patients with Sjögren's syndrome, systemic lupus erythematosus (SLE), vaccination induced vasculitis, Churg-Strauss vasculitis, mixed cryoglobulinaemia associated with hepatitis C infection, or sarcoidosis were included. All developed vasculitic peripheral neuropathy, and were treated with high dose IVIg (2 g/kg body weight). The patients were followed up for 1-5 years after this treatment. RESULTS: In four patients (Sjögren's syndrome, Churg-Strauss vasculitis, SLE, and vaccination induced vasculitis) the neuropathy resolved after IVIg treatment. CONCLUSION: IVIg may be beneficial in cases of resistant vasculitic peripheral neuropathy. IVIg should probably be considered as a sole or adjuvant treatment for patients with contraindications to conventional treatment, or alternatively, for patients in whom conventional treatment has failed.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Peripheral Nervous System Diseases/therapy , Vasculitis/complications , Adult , Aged , Child , Churg-Strauss Syndrome/complications , Cryoglobulinemia/complications , Female , Hepatitis C/complications , Humans , Influenza Vaccines/adverse effects , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Peripheral Nervous System Diseases/complications , Sarcoidosis/complications , Sjogren's Syndrome/complicationsABSTRACT
OBJECTIVE: To evaluate traditional and non-traditional risk factors for subclinical atherosclerosis in systemic lupus erythematosus (SLE). METHODS: A prospective cohort of 78 patients with SLE without overt atherosclerotic disease was studied. SLE clinical and laboratory parameters, disease activity and damage, treatment and traditional risk factors for atherosclerosis were evaluated. At baseline (T1) and after five years' follow up (T2), the serum levels of anti-oxidised palmitoyl arachidonoyl phosphocholine (oxPAPC), anti-heat shock protein 65, and anti-beta(2)-glycoprotein I antibodies and C reactive protein were tested. At T2, intima-media thickness (IMT) was measured using duplex carotid sonography. Thickened intima, plaque, mean IMT (m-IMT), and maximum IMT (M-IMT) were assessed. RESULTS: A thickened intima was seen in 22/78 (28%) patients and plaque in 13/78 (17%). M-IMT and m-IMT were (mean (SD)) 0.77 (0.34) mm and 0.55 (0.15) mm, respectively. Patients with carotid abnormalities were significantly older, had higher blood pressure and total serum cholesterol levels, and had taken a higher prednisone cumulative dosage than those without any lesions. The carotid abnormalities were associated with renal disease and ECLAM >2 at T1, and with azathioprine treatment. In multivariate analysis, age and cumulative prednisone dose were associated with carotid abnormalities; age, hypertension, and anti-oxPAPC at T2 were correlated with higher M-IMT and m-IMT. CONCLUSIONS: In patients with SLE some non-traditional risk factors for atherosclerosis were identified, the most important of which was the cumulative prednisone dose. The role of some traditional risk factors, such as age and hypertension, was also confirmed. The predictive value of the new immunological and inflammatory markers of atherosclerosis seems to be masked by some disease related features.
Subject(s)
Arteriosclerosis/complications , Arteriosclerosis/diagnosis , Lupus Erythematosus, Systemic/complications , Adult , Age Factors , Anti-Inflammatory Agents/therapeutic use , Carotid Arteries/pathology , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Hypertension/pathology , Lupus Erythematosus, Systemic/drug therapy , Lupus Nephritis/pathology , Male , Middle Aged , Multivariate Analysis , Prednisone/therapeutic use , Prospective Studies , Risk Factors , Tunica Intima/pathology , Ultrasonography, Doppler, DuplexABSTRACT
The 10th International Congress on Antiphospholipid Antibodies (Sicily, Italy, September 29-October 3, 2002) (Fig. 1) provided enlightening aspects on the recent developments in antiphospholipid syndrome (APS) and antiphospholipid antibodies in more than 150 lectures and posters. Researchers from all aspects of medicine attended the meeting, implicating the systemic characteristics of APS. The important breakthroughs are summarized.
Subject(s)
Antibodies, Antiphospholipid , Antiphospholipid Syndrome/immunology , Animals , Arteriosclerosis/immunology , HumansABSTRACT
Anti-prothrombin antibodies (aPT) are associated with thrombotic manifestations, and their association with reproductive failure is debatable. The aim of this study was to examine whether aPT could induce thrombosis and other clinical manifestations of the anti-phospholipid syndrome (APS). Mice were immunized with either prothrombin, beta2-glycoprotein-I (beta2GPI), or beta2GPI followed by prothrombin. The presence of clinical manifestation of APS, including thrombocytopenia, lupus anticoagulant and fetal resorption rates, was evaluated in all mice groups compared with nonimmunized mice. Thrombosis was studied in a novel ex-vivo model in which the aorta was sutured for 1 min and the presence or absence of visible thrombus was qualitatively evaluated. Immunized mice developed high autoantibody levels directed towards their immunizing autoantigens. The groups immunized with beta2GPI or beta2GPI/prothrombin, but not with prothrombin alone, developed prolonged aPTT, thrombocytopenia and increased fetal resorption rate. All prothrombin-immunized mice as well as most beta2GPI/prothrombin-immunized mice developed visible thrombus within the aorta. Some beta2GPI immunized mice developed very mild thrombus. None of the CFA/PBS-injected or the nonimmunized mice developed such thrombus. Active immunization with prothrombin or beta2GPI/prothrombin is associated with prothrombotic activity of blood in an ex-vivo model. This is the first direct evidence for thrombus induction by aPT.
Subject(s)
Glycoproteins/immunology , Prothrombin/immunology , Thrombosis/immunology , Animals , Antiphospholipid Syndrome/immunology , Autoantibodies/analysis , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Immunization , Mice , Mice, Inbred BALB C , Pregnancy , beta 2-Glycoprotein IABSTRACT
OBJECTIVES: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. METHODS: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjögren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. RESULTS: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. CONCLUSION: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Primary Myelofibrosis/therapy , Rheumatic Diseases/therapy , Skin/pathology , Aged , Female , Fibrosis , Follow-Up Studies , Humans , Male , Middle Aged , Scleroderma, Systemic/therapyABSTRACT
Transverse myelitis (TM) is a rare manifestation of systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). No uniform therapeutic protocol exists for its treatment, and the prognosis is usually poor. Here we describe four patients having TM associated with antiphospholipid antibodies. Treatment measures and delay in diagnosis between symptom onset and the initiation of treatment varied between patients, but the earlier the diagnosis and the more aggressive the treatment the better was the patient's outcome. Based on these cases and on a literature review we suggest that early aggressive treatment (usually with pulses of methylprednisolone and cyclophosphamide) might improve the prognosis of patients with TM associated with antiphospholipid antibodies.
Subject(s)
Antibodies, Antiphospholipid/analysis , Myelitis, Transverse/immunology , Adult , Aged , Cyclophosphamide/administration & dosage , Cyclophosphamide/therapeutic use , Drug Therapy, Combination , Female , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Injections, Intravenous , Male , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Myelitis, Transverse/diagnosis , Myelitis, Transverse/drug therapy , Myelitis, Transverse/physiopathology , Time FactorsABSTRACT
The identification of specific antimicrobial activity of intravenous immunoglobulin (IVIG) preparations against particular microbial pathogens can assist in determining their therapeutic potential for specific infectious diseases. We analysed five different commercial IVIG preparations for the presence of antibodies directed against a large panel of viral, bacterial, fungal and parasitic pathogens. All IVIG batches contained high activity against herpesviruses types 1, 2, 6 and 7, as well as against varicella zoster virus, Epstein-Barr virus (EBV), measles, mumps, rubella and parvovirus B19. Some IVIG batches also had a significant activity against adenovirus and Saint Louis encephalitis virus. The IVIGs held high activity against several bacterial pathogens, including Mycoplasma pneumonia, Chlamydia pneumonia, Helicobacter pylori and tetanus. No activity was found against various parasitic and fungal pathogens. Our findings may provide further support for the use of IVIG for the prevention and treatment of infections caused by specific viral and bacterial pathogens.
Subject(s)
Antibodies, Bacterial/analysis , Antibodies, Viral/analysis , Communicable Diseases/drug therapy , Immunoglobulins, Intravenous/immunology , Animals , Bacteria/drug effects , Fungi/drug effects , Humans , Immunoglobulins, Intravenous/standards , Microbial Sensitivity Tests , Parasites/drug effectsABSTRACT
Gaucher's disease is characterized by increased incidence of several autoantibodies, but autoimmune phenomena are rare in Gaucher patients. We report the first occurrence of Gaucher's disease and antiphospholipid syndrome in the same patient. A 27-year-old woman with hepatosplenomegaly and thrombocytopenia who was diagnosed as having Gaucher's disease with the genotype 1226G/1226G developed Coombs'-positive hemolytic anemia, recurrent abortions, and a high titer of IgG and IgM anticardiolipin antibodies constituting the diagnosis of antiphospholipid syndrome. A successful pregnancy outcome was achieved by combined therapy with aspirin, low-molecular-weight heparin, prednisone, and enzyme replacement therapy with imiglucerase. The possible pathogenicity of antiphospholipid antibodies found in the sera of many asymptomatic Gaucher patients should be further clarified.
Subject(s)
Antiphospholipid Syndrome/drug therapy , Gaucher Disease/drug therapy , Pregnancy Complications/drug therapy , Pregnancy Outcome , Adult , Anticoagulants/therapeutic use , Antiphospholipid Syndrome/complications , Aspirin/therapeutic use , Drug Therapy, Combination , Female , Gaucher Disease/complications , Glucocorticoids/therapeutic use , Glucosylceramidase/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Platelet Aggregation Inhibitors/therapeutic use , Prednisone/therapeutic use , Pregnancy , Recombinant Proteins/therapeutic useABSTRACT
Is atherosclerosis a cellular or humoral mediated autoimmune disease?
Subject(s)
Arteriosclerosis/immunology , Autoantibodies/immunology , Autoimmune Diseases/immunology , Leukocytes, Mononuclear/immunology , Animals , Antibodies, Anticardiolipin/immunology , Antibodies, Antinuclear/immunology , Cholesterol, LDL/metabolism , Coronary Artery Disease/immunology , Cytokines/immunology , Heat-Shock Proteins/immunology , Humans , Mice , Mice, Transgenic , Models, Animal , Oxidation-ReductionABSTRACT
Magnesium (Mg) fortification of drinking water succeeded in inhibition of atherogenesis development in a transgenic model of atherosclerosis-prone mice fed a high-cholesterol content diet. In order to delineate possible mechanisms of action of the anti-atherogenic effect of Mg, the involvement of LDL oxidation was studied. We determined the susceptibility of LDL to Cu+2 oxidation, anti-oxidized LDL antibody levels, and liver content of retinol and retinyl-palmitate. In order to study another possible mechanism we tested platelets interaction with extracellular matrix in both male and female mice with or without Mg fortification of drinking water. No difference was found in susceptibility of LDL to undergo oxidation. Female mice that received Mg had decreased anti-oxidized LDL antibody levels compared with control female mice, while there was no significant difference among male groups. On the other hand, only in the male group with Mg was a higher content of retinol and retinyl-palmitate found in the livers. Platelets coverage area on extracellular matrix was similar between groups. These results suggest that Mg might affect LDL oxidation, and thus atherogenesis.